Tibet Pharmaceuticals Announces Launch Of New Corporate Website
SHANGRI-LA COUNTY, China, Feb. 9, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (Nasdaq: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announces the launch of a new corporate website.
"We are pleased to announce the launch of our new website," said Taylor Guo, Chief Executive Officer at Tibet Pharmaceuticals. "We now have a website designed from the ground up to provide for a high-quality user experience tailored toward a predominately western audience. As Tibet Pharmaceuticals implements our focused corporate growth and accretive acquisition strategy, we remain committed to providing the public with updates on our progress through standard channels such as press releases, as well as upcoming investor material and multimedia assets made available through our website."
The corporate website provides an overview of Tibet Pharmaceuticals' business model and the company's various opportunities in China's healthcare market and the traditional Tibetan medicine market, in particular. It will prove an important resource for existing shareholders and prospective investors alike.
Tibet Pharmaceuticals' corporate website is available through the following URL:www.tibetpharmaceuticals.com About Tibet Pharmaceuticals, Inc. Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET) is a is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 full-time employees and national-wide distributors, the Company develops both prescription and over-the-counter ("OTC") traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet's products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably the Yunnan Province, where the Company's 52,000 sq. ft. fully GMP-certified manufacturing facilities are located. The access to key raw materials is not generally available outside the province and provides a significant advantage for Tibet. Forward-Looking Statements This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. Specifically, references herein to contemplated acquisitions, industry growth and possible growth in company revenues and/or earnings are forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. SOURCE Tibet Pharmaceuticals, Inc.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.